Last reviewed · How we verify

NCT06704178

A Study to Evaluate the Effects of a Dietary Supplement on Children's Health and Development Outcomes.

Completed NA Results posted Last updated 24 July 2025
What this trial tests

NA trial testing NuBest Tall Growth Protein Powder in Height in 60 participants. Completed in 16 February 2025.

Timeline
12 June 2024
Primary endpoint
16 February 2025
16 February 2025

Quick facts

Lead sponsorNuBest
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposehealth services research
Enrollment60
Start date12 June 2024
Primary completion16 February 2025
Estimated completion16 February 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NuBest

Who can join

Adults 10 to 16, any sex, with Height or Cognitive Function. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change Mean Percentile Score in Double Trouble Primary · Baseline and Month 6

The primary outcome measure will assess the improvement in cognitive function as evaluated by a cognitive test. Participants received a percentile score (1-100) on the assessment, with a higher score indicating a better response.

GroupValue95% CI
Intervention Arm168.55± 230.40
Placebo Arm129.46± 332.76
IChange Mean Percentile Score in Feature Match Primary · Baseline and Month 6

The primary outcome measure will assess the improvement in cognitive function as evaluated by a cognitive test. Feature Match is a focus and processing task. Participants received a percentile score (1-100) on the assessment, with a higher score indicating a better response.

GroupValue95% CI
Intervention Arm34.60± 67.93
Placebo Arm58.20± 147.20
Change Mean Percentile Score in Grammatical Reasoning Primary · Baseline to Month 6

The primary outcome measure will assess the improvement in cognitive function as evaluated by a cognitive test. Grammatical Reasoning is a deductive reasoning task that requires quickly interpreting phrases and making logical conclusions from understanding. Participants received a percentile score (1-100) on the assessment, with a higher score indicating a better response.

GroupValue95% CI
Intervention Arm56.59± 130.07
Placebo Arm88.39± 214.99
Change Mean Percentile Score in Digit Span Primary · Baseline to Month 6

The primary outcome measure will assess the improvement in cognitive function as evaluated by a cognitive test. Digit Span requires users to focus on displayed numbers, hold them in short-term memory, and repeat them back correctly. Participants received a percentile score (1-100) on the assessment, with a higher score indicating a better response.

GroupValue95% CI
Intervention Arm28.02± 60.29
Placebo Arm19.69± 69.38
Change Mean Percentile Score in Token Search Primary · Baseline to Month 6

The primary outcome measure will assess the improvement in cognitive function as evaluated by a cognitive test. Leveraging the brain's executive functioning skills, Token Search requires participants to hold information in working memory and remain focused on completing sequential steps. Participants received a percentile score (1-100) on the assessment, with a higher score indicating a better response.

GroupValue95% CI
Intervention Arm6.26± 36.38
Placebo Arm40.20± 145.02
Increase in Height Secondary · Baseline, Month 2, Month 4, and Month 6

Height measurement will be taken using an Ultrasonic Height Measuring Stadiometer. The increase in height will be tracked over the course of the study.

Month 2
GroupValue95% CI
Intervention Arm0.89± 4.01
Placebo Arm1.16± 6.29
Month 4
GroupValue95% CI
Intervention Arm3.25± 4.19
Placebo Arm1.67± 4.47
Month 6
GroupValue95% CI
Intervention Arm3.47± 5.68
Placebo Arm3.49± 4.54
Changes in Weight Secondary · Baseline, Month 2, Month 4, and Month 6

Weight measurement will be taken using a FitBit Smart Scale. Changes in weight will be analyzed across the groups.

Month 2
GroupValue95% CI
Intervention Arm4.67± 7.83
Placebo Arm4.50± 14.92
Month 4
GroupValue95% CI
Intervention Arm5.52± 5.72
Placebo Arm2.29± 6.80
Month 6
GroupValue95% CI
Intervention Arm7.53± 11.69
Placebo Arm4.65± 5.71
Changes in Overall Health as Reported by Parents Secondary · Monthly from Baseline to Month 6

This parameter was assessed using a parent-completed questionnaire. Parents were required to rate their child's overall health in the past four weeks. Responses were collected using a 5-point Likert scale with textual anchors and transformed into a numerical scale from 1 to 5, where higher scores indicate better outcomes (e.g., 1 = "Very Poor" ," 5 = "Excellent"). An increase in the mean score is associated with improvement in this parameter.

Month 1
GroupValue95% CI
Intervention Arm0.45± 15.09
Placebo Arm0.19± 31.04
Month 2
GroupValue95% CI
Intervention Arm1.22± 13.87
Placebo Arm6.73± 34.70
Month 3
GroupValue95% CI
Intervention Arm-0.51± 15.32
Placebo Arm14.42± 28.39
Month 4
GroupValue95% CI
Intervention Arm3.75± 15.39
Placebo Arm9.17± 27.69
Month 5
GroupValue95% CI
Intervention Arm1.32± 15.12
Placebo Arm17.17± 40.45
Month 6
GroupValue95% CI
Intervention Arm3.27± 14.48
Placebo Arm12.46± 31.13
Change in Parents' Perception of the Child's Health in the Future. Secondary · Monthly from Baseline to Month 6

This parameter was assessed using a parent-completed questionnaire, with the question "I expect my child will have a very healthy life". Responses were collected using a 5-point Likert scale with textual anchors and transformed into a numerical scale from 1 to 5, where higher scores indicate better outcomes (e.g., 1 = "Never," 5 = "Always"). An increase in the mean score is associated with improvement in this parameter.

Month 1
GroupValue95% CI
Intervention Arm16.99± 60.80
Placebo Arm3.53± 32.93
Month 2
GroupValue95% CI
Intervention Arm19.87± 62.14
Placebo Arm7.33± 30.17
Month 3
GroupValue95% CI
Intervention Arm19.55± 60.73
Placebo Arm9.78± 25.46
Month 4
GroupValue95% CI
Intervention Arm18.06± 67.82
Placebo Arm4.86± 22.10
Month 5
GroupValue95% CI
Intervention Arm20.83± 62.55
Placebo Arm8.33± 25.00
Month 6
GroupValue95% CI
Intervention Arm18.67± 61.44
Placebo Arm8.33± 27.13
Parents' Perception of the Change in Child's Health Compared to One Month Ago. Secondary · Monthly from Baseline to Month 6

This parameter was assessed using a parent-completed questionnaire, whereby parents were asked to rate their child's overall health in the past 4 weeks. Responses were collected using a 5-point Likert scale with textual anchors and transformed into a numerical scale from 1 to 5, where higher scores indicate better outcomes (e.g., 1 = "Much worse," 5 = "Much Better"). An increase in the mean score is associated with improvement in this parameter.

Month 1
GroupValue95% CI
Intervention Arm12.82± 23.24
Placebo Arm8.01± 36.25
Month 2
GroupValue95% CI
Intervention Arm18.27± 26.46
Placebo Arm17.33± 38.56
Month 3
GroupValue95% CI
Intervention Arm20.19± 26.68
Placebo Arm25.00± 27.75
Month 4
GroupValue95% CI
Intervention Arm19.44± 23.91
Placebo Arm25.90± 42.88
Month 5
GroupValue95% CI
Intervention Arm12.85± 23.05
Placebo Arm28.99± 30.96
Month 6
GroupValue95% CI
Intervention Arm24.00± 29.00
Placebo Arm24.21± 25.40
Change in Child's Energy Levels as Reported by Parents Secondary · Monthly from Baseline to Month 6

This parameter was assessed using a parent-completed questionnaire. Responses were collected using a 5-point Likert scale with textual anchors and transformed into a numerical scale from 1 to 5, where higher scores indicate better outcomes (e.g., 1 = "Very Poor," 5 = "Excellent"). An increase in the mean score is associated with improvement in this parameter.

Month 1
GroupValue95% CI
Intervention Arm9.17± 18.20
Placebo Arm11.47± 51.50
Month 2
GroupValue95% CI
Intervention Arm5.83± 18.69
Placebo Arm13.20± 20.34
Month 3
GroupValue95% CI
Intervention Arm11.86± 16.02
Placebo Arm26.88± 47.45
Month 4
GroupValue95% CI
Intervention Arm18.75± 24.85
Placebo Arm26.32± 66.60
Month 5
GroupValue95% CI
Intervention Arm15.14± 23.86
Placebo Arm27.61± 65.04
Month 6
GroupValue95% CI
Intervention Arm16.53± 31.79
Placebo Arm15.95± 28.48
Changes in Limitations When Completing High-Intensity Activity Secondary · Monthly from Baseline to Month 6

This parameter was assessed using a parent-completed questionnaire. Responses were collected using a 5-point Likert scale with textual anchors and transformed into a numerical scale from 1 to 5, where lower scores indicate better outcomes (e.g., 1 = "Never," 5 = "Always"). An increase in the mean score is associated with improvement in this parameter.

Month 1
GroupValue95% CI
Intervention Arm8.33± 43.27
Placebo Arm3.85± 67.22
Month 2
GroupValue95% CI
Intervention Arm12.18± 46.80
Placebo Arm0.00± 29.27
Month 3
GroupValue95% CI
Intervention Arm6.41± 46.92
Placebo Arm-13.77± 21.70
Month 4
GroupValue95% CI
Intervention Arm0.00± 25.54
Placebo Arm-7.64± 50.12
Month 5
GroupValue95% CI
Intervention Arm6.25± 49.59
Placebo Arm-13.04± 23.00
Month 6
GroupValue95% CI
Intervention Arm-2.00± 26.93
Placebo Arm0.00± 72.65

Sponsor's own description

A 6-month virtual two-armed randomized double-blind placebo-controlled clinical trial. Participants will take NuBest Tall Growth Protein Powder or a placebo daily. Parents will complete questionnaires at baseline and monthly, and children will undergo cognitive assessments and height/weight measurements at specified intervals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06704178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing